Alternative therapeutic strategies such as targeting lysosomal Pgp (e.g., thiosemicarbazone anti-cancer agents) or use of monoclonal anti-Pgp antibodies provide a promising opportunity to develop effective treatments to overcome MDR in TNBCs. Here, PGP is linked to cancer.